NeutroSpec Withdrawn For Safety Reasons Shortly After “Dear Doctor” Letter
Executive Summary
FDA requested the market withdrawal of Palatin/Mallinckrodt's NeutroSpec less than three weeks after the companies issued a "Dear Healthcare Provider" letter addressing potential safety concerns with the imaging agent